CTV 05

Drug Profile

CTV 05

Alternative Names: CTV-05; LACTIN-V; Lactobacillus crispatus CTV-05

Latest Information Update: 13 May 2016

Price : $50

At a glance

  • Originator GyneLogix
  • Developer National Institute of Allergy and Infectious Diseases; Osel Inc
  • Class Probiotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bacterial vaginosis; Urinary tract infections

Most Recent Events

  • 11 May 2016 Phase-II clinical trials in Bacterial vaginosis (Prevention, Recurrent) in USA (Vaginal)
  • 21 Jul 2015 Phase II development for Urinary tract infections and Bacterial vaginosis is ongoing
  • 01 Apr 2012 Osel completes a phase II trial for Urinary tract infections prevention in USA (NCT00305227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top